GlassScriptPhysician profile
Bernard Perez
NPI 1407837032
$8,833.77
in general payments reported to CMS, 2019-2025
37 companies · $1,535 in 2025
The $1,535 reported for 2025 was more than what 85% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,263 · 2020: $1,165 · 2021: $1,166 · 2022: $941 · 2023: $1,424 · 2024: $1,339 · 2025: $1,535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,298.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $1,100.31 | 2020-2025 | Acthar |
| Horizon Therapeutics Plc | $1,042.90 | 2019-2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $770.33 | 2019-2025 | Cequa |
| Alcon Vision LLC | $760.48 | 2019-2025 | Rocklatan, Tryptyr, Argos |
| Ani Pharmaceuticals, INC. | $528.39 | 2022-2025 | Purified Cortrophin Gel, Iluvien |
| Mallinckrodt Enterprises LLC | $468.60 | 2019 | |
| Bausch & Lomb Americas INC. | $419.42 | 2023-2025 | Xiidra, Miebo, Vyzulta |
| Alimera Sciences, INC. | $416.42 | 2019-2024 | Yutiq, Iluvien |
| Novartis Pharmaceuticals Corporation | $379.09 | 2019-2023 | |
| Sight Sciences, INC. | $370.47 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Oyster Point Pharma, INC. | $363.38 | 2022-2024 | Tyrvaya, Ryzumvi |
| Allergan, INC. | $315.11 | 2019-2022 | |
| Abbvie INC. | $292.35 | 2019-2025 | |
| Dompe US, INC. | $287.00 | 2022-2025 | Oxervate |
| Amgen INC. | $137.30 | 2024-2025 | Tepezza |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $135.59 | 2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $116.35 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $108.85 | 2024-2025 | Syfovre |
| Kala Pharmaceuticals, INC. | $102.77 | 2021 | |
| Aerie Pharmaceuticals, INC. | $98.65 | 2019-2021 | |
| Harrow Eye, LLC | $79.71 | 2024-2025 | Iheezo, Triesence, Verkazia |
| Shire North American Group INC | $79.19 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $70.59 | 2020-2024 | Eylea Hd |
| Ocular Therapeutix, INC. | $67.06 | 2021-2025 | Dextenza |
| Glaukos Corporation | $53.64 | 2020-2023 | |
| Astellas Pharma US INC | $50.78 | 2025 | Izervay |
| Biotissue Holdings INC. | $46.56 | 2025 | |
| Thea Pharma INC. | $43.22 | 2022-2023 | Iyuzeh |
| Johnson & Johnson Surgical Vision, INC. | $21.64 | 2021 | |
| Neurotech Pharmaceuticals, INC. | $21.17 | 2025 | |
| Ivantis, INC | $20.08 | 2020 | |
| Eyevance Pharmaceuticals LLC | $19.20 | 2020 | |
| Iridex Corporation | $16.62 | 2019 | |
| Omeros Corporation | $16.46 | 2019 | |
| Tearlab Corp | $14.09 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.